Clinical Trial Update: Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial update for TT-173 evaluating its efficacy in reducing total blood loss during total knee arthroplasty in degenerative osteoarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Osteoarthritis
• Total Knee Arthroplasty

Drugs mentioned

• TT-173

Snippet

Sponsor: Thrombotargets Europe S.L | Conditions: Degenerative Osteoarthritis | Phase 2, Phase 3 | Status: UNKNOWN